دورية أكاديمية
أعرض في EDS

Having it both ways: how STAT3 deficiency blocks graft-versus-host disease while preserving graft-versus-leukemia activity.

التفاصيل البيبلوغرافية
العنوان: Having it both ways: how STAT3 deficiency blocks graft-versus-host disease while preserving graft-versus-leukemia activity.
المؤلفون: Brandstadter JD, Outen R, Maillard I
المصدر: The Journal of clinical investigation [J Clin Invest] 2023 Aug 01; Vol. 133 (15). Date of Electronic Publication: 2023 Aug 01.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Graft vs Host Disease*/genetics , Graft vs Host Disease*/therapy , Leukemia*/pathology , Hematopoietic Stem Cell Transplantation*, Humans ; T-Lymphocytes ; Graft vs Leukemia Effect ; STAT3 Transcription Factor/genetics
مستخلص: Allogeneic hematopoietic cell transplantation can cure patients with high-risk leukemia through graft-versus-leukemia (GVL) effects, the process by which malignant leukemic cells are cleared by donor-derived immune cells from the graft. The problem of harnessing GVL effects while controlling inflammation and host-organ damage linked with graft-versus-host disease (GVHD) has been the most formidable hurdle facing allogeneic hematopoietic cell transplantation. This powerful, curative-intent therapy remains among the most toxic treatments in the hematologist's armamentarium due to the combined risks of GVHD-related morbidity, infections, and leukemia relapse. In this issue of the JCI, Li, Wang, et al. report that T cell Stat3 deficiency can extricate GVL effects from GVHD through tissue-specific programmed death-ligand 1/programmed cell death protein 1-dependent (PD-L1/PD-1-dependent) bioenergetic alterations that blunt harmful T cell effects in GVHD target organs, while preserving their beneficial antitumor activity in lymphohematopoietic tissues.
References: J Clin Invest. 2017 May 1;127(5):1960-1977. (PMID: 28414296)
Blood. 2008 Dec 15;112(13):5254-8. (PMID: 18838616)
J Immunol. 2010 Jan 15;184(2):764-74. (PMID: 19995899)
J Clin Invest. 2021 Jan 4;131(1):. (PMID: 32931481)
Sci Transl Med. 2023 Jun 28;15(702):eadd1175. (PMID: 37379368)
Blood. 2021 Dec 16;138(24):2583-2588. (PMID: 34424962)
Immunity. 2023 Feb 14;56(2):369-385.e6. (PMID: 36720219)
Blood. 2021 Apr 8;137(14):1970-1979. (PMID: 33512442)
Hematology Am Soc Hematol Educ Program. 2015;2015:225-30. (PMID: 26637726)
J Immunol. 2003 Aug 1;171(3):1272-7. (PMID: 12874215)
Immunity. 2017 Jun 20;46(6):1089-1090. (PMID: 28636957)
Immunity. 2012 Aug 24;37(2):209-22. (PMID: 22921119)
J Clin Invest. 2016 Apr 1;126(4):1337-52. (PMID: 26950421)
Cancer Cell. 2019 Nov 11;36(5):498-511.e17. (PMID: 31715132)
Blood. 2022 Dec 22;140(25):2740-2753. (PMID: 36084473)
Blood. 2017 Jul 13;130(2):221-228. (PMID: 28468799)
JCI Insight. 2020 May 7;5(9):. (PMID: 32255769)
Front Immunol. 2022 Feb 28;13:751296. (PMID: 35296079)
Blood. 2021 Apr 22;137(16):2243-2255. (PMID: 33511398)
معلومات مُعتمدة: R01 AI091627 United States AI NIAID NIH HHS; T32 HL007439 United States HL NHLBI NIH HHS
المشرفين على المادة: 0 (STAT3 protein, human)
0 (STAT3 Transcription Factor)
تواريخ الأحداث: Date Created: 20230801 Date Completed: 20230802 Latest Revision: 20230825
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10378150
DOI: 10.1172/JCI172251
PMID: 37526083
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI172251